Exhibit 99.1
Atossa Genetics Announces Third Quarter 2014 Financial Results
and Provides Company Update
Conference Call to be Held Today at 4:30 pm Eastern Time
SEATTLE, November 12, 2014 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced Third Quarter 2014 financial results and provided an update on recent corporate developments.
“In October our subsidiary, The National Reference Laboratory for Breast Health, Inc., or the NRLBH, began offering a new pharmacogenomics test” stated Dr. Steven C. Quay, Chairman, CEO and President. “These genetic tests, which help doctors prescribe drugs and doses best suited for each person, are being sold by the NRLBH’s sales and marketing partner, BioVentive, Inc. In the past three weeks, the NRLBH has processed approximately 238 pharmacogenomics tests. We have been seeing a strong demand for pharmacogenomics tests and expect they will provide a positive financial contribution to our business while complementing our other tests under development. We also continue to make significant progress towards introducing the ForeCYTE Breast Aspirator into the European markets – having now received the CE Mark - and developing the FullCYTE Breast Aspirator for a planned launch in the United States.”
Recent Corporate Developments
Important recent corporate developments include the following:
| · | The NRLBH launched pharmacogenomics testing in October and has now processed approximately 238 tests. |
| · | Hired Scott Youmans as Senior Vice President of Operations, a seasoned medical device executive. |
| · | Retained BioVentive, Inc. to provide sales and marketing services to the NRLBH. |
| · | Obtained a CE Mark for the ForeCYTE Breast Aspirator, which is a significant milestone in our plans to launch the device in key European markets. |
| · | Received a complete dismissal with prejudice of the securities class action lawsuit filed against Atossa and certain officers and directors in October 2013 (which the plaintiffs have now appealed to the U.S. Ninth Circuit Court of Appeals). |
Third Quarter 2014 Financial Results
Revenue for the three months and nine months ended September 30, 2014, totaled $3,426 and $37,425, consisting of additional cash collected in excess of the amounts we accrued previously at the Medicare rates. Total revenue for the three and nine months ended September 30, 2013 was $76,597 and $585,345. Cost of revenue was $0 for the three months and nine months ended September 30, 2014, compared to $25,938 and $314,562 in the same periods in 2013.
For the three months and nine months ended September 30, 2014, gross profit totaled $3,426 and $37,425, compared to $50,659 and $270,783 in the same period in 2013.
Operating expenses for the three months ended September 30, 2014 were $3,248,681 consisting of general and administrative (G&A) expenses of $2,043,138, research and development (R&D) expenses of $923,169, and selling expenses of $282,374, representing an decrease of $303,875, or 9% from $3,552,556 in the same period in 2013, which consisted of G&A expenses of $2,858,027, R&D expenses of $321,111, and selling expenses of $373,418. Operating expenses for the nine months ended September 30, 2014 were $8,880,138 consisting of G&A expenses of $6,280,102, R&D expenses of $1,856,439, and selling expenses of $743,597. Operating expenses increased $582,678, or 7% from $8,297,460 for the same period in 2013, which consisted of $6,600,819 in G&A expenses, $731,258 in R&D expenses, and $965,383 in selling expenses.
G&A expenses decreased primarily as a result of lower capital raising commissions, lower recall expenses, lower consulting fees, lower advertising and marketing fees and lower bad debt expenses, offset by higher legal and regulatory and higher salaries, director fees and employees benefits. Selling expenses decreased primarily as a result of our reduced sales and marketing efforts after our voluntary recall in October 2013. R&D increased primarily as a result of increased expenditures on the development of our new products and tests in the pipeline, including the NextCYTE Test and FullCYTE microcatheters.
We expect that our G&A and selling expenses will increase in future periods as we hire additional administrative and manufacturing personnel to prepare for and execute on the launch of the ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, and our other products and services under development, and as we incur additional costs associated with being a publicly traded company. We also expect that our R&D expenses will continue to increase as we add additional full time employees and incur additional costs to continue the development of our products and services under development throughout 2014.
Conference Call Information
Management will host a conference call today, November 12, 2014, at 4:30 pm Eastern Time to review the financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. may dial 866-652-5200 or 412-317-6060 for international callers. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast atwww.atossagenetics.com.
A replay of the call will be available one hour after the end of the call through September 12, 2014, and can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international). The replay conference ID number is 10046259.
About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visitwww.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including the outcome of the FDA re-inspection completed on March 14, 2014, the outcome or timing of regulatory clearances, Atossa's ability to continue to manufacture and sell its products in a timely fashion, recalls of products, the efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets it tests, devices and therapeutics in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Contact:
Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Kyle.Guse@atossagenetics.com
Investor Relations:
CorProminence LLC
Scott Gordon
President
516-222-2560
scottg@corprominence.com
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| | | September 30, | | | December 31, | |
| | | 2014 | | | 2013 | |
| | | (Unaudited) | | | (Audited) | |
| Assets | | | | | | |
| Current assets | | | | | | |
| Cash and cash equivalents | | $ | 11,374,251 | | | $ | 6,342,161 | |
| Accounts receivable, net | | | 29,151 | | | | 139,072 | |
| Prepaid expense | | | 266,726 | | | | 280,627 | |
| Inventory, net | | | 45,867 | | | | - | |
| Total current assets | | | 11,715,995 | | | | 6,761,860 | |
| | | | | | | | | |
| Furniture and equipment, net | | | 185,000 | | | | 163,147 | |
| Intangible assets, net | | | 4,365,312 | | | | 4,395,633 | |
| Deferred financing costs | | | 426,961 | | | | 651,961 | |
| Security deposit | | | 78,958 | | | | 36,446 | |
| Total assets | | $ | 16,772,226 | | | $ | 12,009,047 | |
| | | | | | | | | |
| Liabilities and Stockholders' Equity | | | | | | | | |
| | | | | | | | | |
| Current liabilities | | | | | | | | |
| Accounts payable | | $ | 439,248 | | | $ | 248,142 | |
| Accrued expenses | | | 393,704 | | | | 399,478 | |
| Deferred rent | | | 8,549 | | | | 48,157 | |
| Payroll liabilities | | | 682,356 | | | | 476,477 | |
| Product recall liabilities | | | 3,385 | | | | 211,493 | |
| Other current liabilities | | | 12,375 | | | | 23,649 | |
| Total current liabilities | | | 1,539,617 | | | | 1,407,396 | |
| | | | | | | | | |
| Stockholders' Equity | | | | | | | | |
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and
outstanding at September 30, 2014 and December 31, 2013, respectively | | | - | | | | - | |
Common stock - $.001 par value; 75,000,000 shares authorized, 24,564,058 and 18,574,334
shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively | | | 24,564 | | | | 18,574 | |
| Additional paid-in capital | | | 44,569,561 | | | | 31,099,691 | |
| Accumulated deficit | | | (29,361,516 | ) | | | (20,516,614 | ) |
| Total stockholders' equity | | | 15,232,609 | | | | 10,601,651 | |
| | | | | | | | | |
| Total liabilities and stockholders' equity | | $ | 16,772,226 | | | $ | 12,009,047 | |
ATOSSA GENETICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| | | For the Three Months Ended
September 30, | | | For The Nine Months Ended
September 30, | |
| | | 2014 | | | 2013 | | | 2014 | | | 2013 | |
| Revenue | | | | | | | | | | | | |
| Diagnostic testing service | | $ | 3,426 | | | $ | 72,187 | | | $ | 37,425 | | | $ | 361,905 | |
| Product sales | | | - | | | | 4,410 | | | | - | | | | 223,440 | |
| Total Revenue | | | 3,426 | | | | 76,597 | | | | 37,425 | | | | 585,345 | |
| Cost of Revenue | | | | | | | | | | | | | | | | |
| Diagnostic testing service | | | - | | | | 25,938 | | | | - | | | | 75,893 | |
| Product sales | | | - | | | | - | | | | - | | | | 238,669 | |
| Total Cost of Revenue | | | - | | | | 25,938 | | | | - | | | | 314,562 | |
| Gross Profit | | | 3,426 | | | | 50,659 | | | | 37,425 | | | | 270,783 | |
| Selling expenses | | | 282,374 | | | | 373,418 | | | | 743,597 | | | | 965,383 | |
| Research and development expenses | | | 923,169 | | | | 321,111 | | | | 1,856,439 | | | | 731,258 | |
| General and administrative expenses | | | 2,043,138 | | | | 2,858,027 | | | | 6,280,102 | | | | 6,600,819 | |
| Total operating expenses | | | 3,248,681 | | | | 3,552,556 | | | | 8,880,138 | | | | 8,297,460 | |
| Operating Loss | | | (3,245,255 | ) | | | (3,501,897 | ) | | | (8,842,713 | ) | | | (8,026,677 | ) |
| Interest income | | | 11 | | | | 53 | | | | 154 | | | | 53 | |
| Interest expense | | | 151 | | | | 1 | | | | 2,343 | | | | 360 | |
| Loss before Income Taxes | | | (3,245,395 | ) | | | (3,501,845 | ) | | | (8,844,902 | ) | | | (8,026,984 | ) |
| Income Taxes | | | - | | | | - | | | | - | | | | - | |
| Net Loss | | $ | (3,245,395 | ) | | $ | (3,501,845 | ) | | $ | (8,844,902 | ) | | $ | (8,026,984 | ) |
| Loss per common share - basic and diluted | | $ | (0.13 | ) | | $ | (0.22 | ) | | $ | (0.37 | ) | | $ | (0.55 | ) |
| Weighted average shares outstanding, basic & diluted | | | 24,537,379 | | | | 15,830,033 | | | | 23,860,843 | | | | 14,697,221 | |
